Long-term efficacy of rituximab in chronic ataxic neuropathy associated with anti-ganglioside antibodies.

Neurologia (Engl Ed)

Unidad de Enfermedades Neuromusculares, Departamento de Neurología, Hospital del Mar, Barcelona, Spain. Electronic address:

Published: November 2021

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nrleng.2021.02.006DOI Listing

Publication Analysis

Top Keywords

long-term efficacy
4
efficacy rituximab
4
rituximab chronic
4
chronic ataxic
4
ataxic neuropathy
4
neuropathy associated
4
associated anti-ganglioside
4
anti-ganglioside antibodies
4
long-term
1
rituximab
1

Similar Publications

Initial experience of a novel surgical assist robot "Saroa" featuring tactile feedback and a roll-clutch system in radical prostatectomy.

Sci Rep

December 2024

Department of Urology, The Jikei University School of Medicine, Kashiwa Hospital, Kashiwashita 163-1, Kashiwa, Chiba, 277-8567, Japan.

To evaluate the safety and efficacy of the Saroa Surgical Robot System in robot-assisted laparoscopic radical prostatectomy (RARP). We enrolled 60 patients who underwent RARP using either the Saroa (n = 9) or da Vinci Xi (n = 51) systems at Jikei University Kashiwa Hospital from January 2022 to March 2024. We compared preoperative characteristics, perioperative outcomes, complications, and postoperative urinary continence at three months between the two groups.

View Article and Find Full Text PDF

Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mPDAC) or castration-resistant prostate cancer (mCRPC). Primary objectives were to evaluate safety and tolerability and determine the recommended phase 2 dose/schedule (RP2D). Secondary objectives included the assessment of efficacy and characterization of the pharmacokinetics of rimiducid.

View Article and Find Full Text PDF

Relations among territoriality, abundance and habitat suitability are fundamental to the ecology of many animal populations. Theory suggests two classes of possible responses to increasing abundance in territorial species: (1) the ideal free distribution (IFD), which predicts smaller territory sizes and decreased fitness as individuals adaptively pack into suitable habitats, and (2) the ideal despotic distribution (IDD), which predicts stable territory sizes and fitness in preferred habitats for dominant individuals and increased use of marginal habitats, reduced fitness and changes in territory sizes for subordinate individuals. We analysed the territory sizes and locations of seven migratory songbird species occupying a 10-ha plot in the Hubbard Brook Experimental Forest, New Hampshire, USA over a 52-year period.

View Article and Find Full Text PDF

Introduction Respiratory distress syndrome (RDS) is a leading cause of morbidity and mortality among preterm infants, necessitating effective treatment strategies. This study compared the efficacy of Beractant (SURVANTA®) to Poractant alfa (CUROSURF®) in treating RDS in preterm infants admitted to Tawam Hospital in the UAE. Methodology This retrospective study included preterm infants from 23+0 to 36+6 weeks of gestation with a diagnosis of RDS and treatment by Beractant or Poractant alfa within 48 hours of life between January 2020 and March 2023.

View Article and Find Full Text PDF

Background Ninjin'yoeito (NYT), a traditional Japanese Kampo medicine, has shown potential in treating frailty and overactive bladder (OAB) symptoms. However, its effects are multifaceted and vary among individuals. This pilot study explored the use of topological data analysis (TDA) and natural language processing (NLP) to evaluate the effect of NYT on frailty in patients with OAB.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!